

14<sup>th</sup> May 2025

To,

**BSE LIMITED** Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001 **THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (East) Mumbai - 400051

Dear Sir,

#### Sub: Advertisement relating to Financial Results

Pursuant to clause 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), we enclose advertisements given in Economic Times, Business Standard and Maharashtra Times relating publication of Audited Financial Results for quarter & year ended 31<sup>st</sup> March 2025.

Thanking you,

Yours faithfully For **GlaxoSmithKline Pharmaceuticals Limited** 

Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary

**Encl: Public Notice** 

CIN: L24239MH1924PLC001151

PubDate: 14-05-2025 Zone: Mumbai Edition: 1 Page: MTMP7 User: maruti.gaikwad





नैसर्गिक अति वाळच्य ∞== उत्खननामळे निर्माण होणाऱ्या Ξपर्यावरणीय संकटांना आळा बसावा तसेच बांधकामक्षेत्राला पर्यायी व टिकाऊ साधन उपलब्ध व्हावे. राज्यात कृत्रिम वाळूच्या =(एम-सॅंड) उत्पादन व वापर मंगळवारी झालेल्या =धोरणास मंत्रिमंडळ बैठकीत मान्यता देण्यात 🗕 डआली. या बैठकीच्या अध्यक्षस्थानी ∃मुख्यमंत्री देवेंद्र फडणवीस होते. या सार्वजनिक -धोरणानुसार वांधकामांमध्ये या कृत्रिम वाळूचा =वापर वाढावा यासाठी प्रोत्साहन दिले =जाणार आहे

राज्यात वाळूच्या उत्पादनासाठी 🚉 स्वामित्वधन म्हणून प्रतिब्रास ६०० ेरुपये आकारण्यात येते, त्याऐवजी 🗄 प्रतिब्रास २०० रुपये सवलतीच्या जें चेंदराने स्वामित्वधन (रॉयल्टी) .≟आकारण्यास बैठकीत मंज़्री देण्यात डआली. क्वॉरी वेस्ट व डोंगर 🗄 उत्खननातून मिळणाऱ्या दगडांपासून -क्रेशरच्या साह्याने तयार होणारी ही 式 📑 कुत्रिम वाळू नैसर्गिक वाळूला पर्याय ठरू शकते, या धोरणानुसार, जिल्हा ेंप्रशासन व वन विभागाच्या ∞ =परवानगीनंतर एम-सॅंड युनिट्स ∃उभारण्यास परवानगी देण्यात येणार 🖃 असून, पर्यावरणीय नियमांचे पालन -आवश्यक राहील. राज्यातील सर्व शासकीय,



आपल्या बांधकाम प्रकल्पांमध्ये एम-सेंड युनिट्समुळे स्थानिक एम-सॅंडचा प्राधान्याने वापर करावा. पातळीवर अशा सूचना शासनाने दिल्या आहेत. याशिवाय, भारतीय मानक विभागाच्या गुणवत्ताधारित एम-सॅंडचाच वापर करण्यात यावा, असे स्पष्ट करण्यात आले आहे. कृत्रिम वाळू (एम-सँड) धोरणास मंजुरी - प्रत्येक जिल्ह्यात ५० व्यक्ती/ संस्थांना एम-सँड युनिट स्थापन करण्यासाठी उद्योगविभाग सवलती आहे. जाणार देणार आहे. तसेच एम-सँड तयार बांधकामक्षेत्रात या निर्णयामुळे मोठा करणाऱ्या युनिटला प्रतिब्रास २००

रोजगाराच्या वाढतील, तसेच नैसर्गिक वाळवरील अवलंबित्व कमी होऊन पर्यावरण रक्षणास हातभार लागेल. सरकारचा विश्वास आहे. यासाठी जिल्हास्तरीय समित्या करण्यात येणार असून, काटेकोर अंमलबजावणी करण्यासाठी स्वतंत्र निरीक्षण यंत्रणा तयार केली

बदल होण्याची शक्यता आहे.

GSK

संधी

असा

स्थापन

धोरणाची

राज्यातील



जीव्हीएस फार्मा लिमिटेड ब्लिस CIN No - L24230MH1984PLC034771

नोंदणीकृत कार्यालयः १०२, हाईड पार्क, साकी नाका रोड, साकी विहार, अंधेरी (पूर्व), मुंबई - ४०००७२ इमेलः cs@blissgvs.com
 वेबसाईट: www.blissgvs.com

## ३१ मार्च २०२५ रोजी संपलेल्या तिमाही आणि वर्षासाठी लेखापरीक्षित स्वतंत्र आणि एकत्रित आर्थिक निकालांचे विवरणपत्र

कंपनीच्या संचालक मंडळाने सोमवार, १२ मे २०२५ रोजी झालेल्या बैठकीत ३१ मार्च २०२५ रोजी संपलेल्या तिमाही आणि वर्षासाठी कंपनीच्या लेखापरीक्षित स्वतंत्र आणि एकत्रित आर्थिक निकालांना मान्यता दिली.

कंपनीच्या आर्थिक निकालांचे संपूर्ण स्वरूप, स्टॉक एक्सचेंजच्या वेबसाइट www.bseindia.com आणि www.nseindia.com वर उपलब्ध आहे आणि कंपनीच्या वेबसाइट https://blissgvs.com/investors/ financials/quarterly-reports/ वर देखील पोस्ट केले आहे जे क्विक रिस्पॉन्स (QR) कोड स्कॅन करून ॲक्सेस करता येते.



ब्लिस जीव्हीएस फार्मा लिमिटेड करिता स्वाक्षरी गगन हर्ष शर्मा व्यवस्थापकीय संचालक डीआयएन क्र. ०७९३९४२१

-8

5

22

49

- 49

4-

46

42

4

43

42

4

4

8

8

34

8

33

8

33-

8

5

9

58

58

2

-8

-8

24

33

2

2

2

Ø

9

2

4

3

ठिकाण: मुंबई तारीख: १२ मे २०२५

टीपः वरील सूचना सेबी (लिस्टिंग ऑब्लिगेशन्स अँड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन ४७(१) सह वाचलेल्या रेग्युलेशन ३३ नुसार आहे.

## GlaxoSmithKline Pharmaceuticals Limited

Registered Office: GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030 · Website: https://india-pharma.gsk.com/en-in/ Email: in.investorquery@gsk.com · Corporate Identity Number: L24239MH1924PLC001151

STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31<sup>57</sup> MARCH, 2025

## 🛚 घेतली राज यांची भेट

उदय सामत यानी

🛛 📴 म. टा. विशेष प्रतिनिधी, पनवेल

शिवसेना नेते उदय सामंत यांनी मंगळवारी महाराष्ट्र नवनिर्माण 🗄 सेनेचे अध्यक्ष राज ठाकरे यांची भेट S = चेतली. या भेटीमुळे आगामी ∃स्थानिक स्वराज्य संस्थांच्या ानिवडण्का लक्षात घेऊन मनसे 🗄 आणि शिवसेना युतीबाबत चर्चा सरू झाल्याचे बोलले जात असले 🕄 🗄 तरी राज ठाकरे यांच्यासोबत <sup>Ξ</sup>अराजकीय चर्चा झाल्याचे सामंत 🗄 यांनी सांगितले. मनसेचे नेते संदीप ेदेशपांडे यांनीही या भेटीच्या वृत्तास दुजोरा दिला.

\Xi राज ठाकरे यांच्या भेटीनंतर उदय सामंत यांनी प्रसारमाध्यमांशी इसंवाद साधला. 'सकाळी काही 8 कामासाठी मी या भागात आलो इंहोतो. त्यामुळे राज ठाकरे यांना ω...Ξफोन केला. मी गप्पा मारण्यासाठी 3येत असल्याचे सांगितले. त्यांनाही =वेळ होता. त्यांनी होकार दिला. राज 👸 🗄 ठाकरे यांच्यासोबत चर्चा केल्यावर =अनेक विषय कळतात. \_विकासाबाबत माहिती मिळते. ैत्यामुळे ही अराजकीय भेट होती. ैपरंतु तुमच्या मनात जी शंका आहे

♀=ती कोणतीही चर्चा झाली नाही. अतिशय चांगली चर्चा झाली. -खाल्ली आणि निघालो, ' असेही ते -म्हणाले

ञ्ज\_\_\_\_\_\_ मुंबई महानगरपालिकेच्या निवडणुकीबाबत चर्चा झाली का,

37

आधुनिकीकरण 👌 🗄 म. टा. खास प्रतिनिधी, मुंबई राज्यातील शासकीय 🕂 🗄 औद्योगिक प्रशिक्षण संस्थांचे सार्वजनिक E( आयटीआय ) 🔁 🔤 अद्ययावतीकरण करण्याचे धोरण कोटी रुपये निश्चित करण्यात आले आहेत. राबविण्यास राज्य मंत्रिमंडळाच्या —वैठकीत मंगळवारी मंजरी देण्यात औद्योगिक प्रशिक्षण इमारतीची मालकी शासनाकडे आली राहील. :संस्थांना जागतिक दर्जाच्या सरकारची धोरणे कायम राहतील म् अशिक्षण केंद्रांमध्ये रूपांतरित 🗄 करण्याचे उद्दिष्ट या धोरणात आहे. शिक्षक कर्मचाऱ्यांसह कर्मचारी 🖃 या प्रशिक्षण केंद्रातन उद्योगांच्या कायम =मागणीनुसार प्रशिक्षणार्थी घडवणे तंत्रज्ञानावर आधारित प्रशिक्षण आणि अभ्यासक्रम राबविण्यासाठी ैक \_\_\_\_\_ भर दिला जाणार आहे. अतिरिक्त कर्मचारी भागीदार



निकषानुसार

असे विचारले असता. 'मंबई मनपासंदर्भात चर्चा झाली असती तर मी जाहीरपणे सांगितले असते. त्यासाठी पत्रकार परिषद घेतली असती. आजची भेट ही अराजकीय होती. आता मी एकनाथ शिंदे यांना भेटण्यासाठी जाणार आहे. त्यामळे तम्ही म्हणाल, राज ठाकरे यांच्यासोबत झालेली चर्चा एकनाथ शिंदे यांना सांगणार ? परंत् तसे काही नाही, माझी आणि राज ठाकरे यांची चौथी भेट आहे. आजच्या चर्चेत कोणतीही राजकीय खिचडी झाली नाही,' असेही ते म्हणाले. तेजस्वी घोसाळकर यांच्या राजीनाम्याबाबतही त्यांनी भाष्य केले. ' अनेक नेते शिवसेना उबाठा सोडत आहे. त्यामुळे उद्धव ठाकरे यांनी आता आत्मचिंतन करायला हवे. एकनाथ शिंदे यांच्या कामामुळे हे नेते शिवसेनेत येत आहे.

राज्यभरात शिवसेनेत इनकमिंग वाढले आहे,' असे त्यांनी सांगितले.

सार्वजनिक-खासगी

भागीदारी धोरणास

आयटीआयच्या जागेची आणि

राहतलि

आयटीआयबाबत

नवीन

मंजुरी

			Standalone						Consolidated				
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)		
	Particulars	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year endeo 31.03.2024		
1	Revenue from continuing operations	96608	94636	91087	372349	340725	97437	94942	92980	374921	34537		
2	Profit before Exceptional Items and tax	35490	30635	26631	124375	95265	35857	30810	26822	125519	9598		
3	Exceptional Items [credit / (charge)]	-	-	240	469	(14361)	944) 1	1	240	469	(1436		
4	Profit before tax	35490	30635	26871	124844	80904	35857	30810	27062	125988	8161		
5	Net Profit after tax	26014	22858	19308	91906	58469	26287	22988	19448	92758	5899		
6	Total comprehensive income for the period	25630	22976	19239	91640	58052	25903	23106	19379	92492	585		
7	Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	16941	16941	16941	16941	16941	16941	16941	16941	1694		
8	Other Equity	-	-	-	177982	161468	100	1. 1.	-	178190	1608		
9	Earnings Per Share (EPS) (of ₹ 10 each)												
	Basic and diluted EPS before Exceptional Items (₹)	15.35	13.49	11.29	54.01	40.83	15.52	13.57	11.37	54.52	41.		
	Basic and diluted EPS after Exceptional Items (₹)	15.35	13.49	11.39	54.24	34.51	15.52	13.57	11.48	54.76	34.		
			Not A			Not /	Annualised						

#### Notes:

15

1. The above is an extract of the detailed format of the Financial Results for the quarter and year ended March 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com. The same can be assessed by scanning the QR code. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 13<sup>th</sup> May, 2025. 3. The Board of Directors recommended a final Dividend of Rs. 42 per equity share of face value of Rs.10 each (Year ended 31<sup>st</sup> March 2024 Rs. 32 per equity share).



By Order of the Board Bhushan Akshikar Managing Director DIN: 09112346

Place: Mumbai Date: 13th May, 2025



CIN: L17116MH1978PLC020451

Regd. Office: H-3/2, MIDC, 'A' Road, Tarapur, Boisar, Dist. Palghar, PIN 401 506 (M.S.),

Phone - 022-3040 0500; Email - sharedept@siyaram.com; Website - www.siyaram.com

#### EXTRACT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER

AND YEAR ENDED 31<sup>st</sup> MARCH, 2025.

N (₹In Lakhs)

		S	TANDALO	NE		CONSOLIDATED					
PARTICULARS	Q	Quarter Ended		Year Ended		Quarter Ended			Year Ended		
PARTICULARS	31.03.2025 (Audited)	31.12.2024 (Unaudited)		31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)	31.12.2024 (Unaudited)			31.03.2024 (Audited)	
Revenue from Operations	73607.75	57017.36	64636.93	222031.86	208717.60	73,619.22	57,072.91	64,777.49	2,22,161.91	2,09,205.46	
Other Income	1359.36	1622.93	640.58	7530.08	3754.55	1,359.54	1,622.93	640.52	7,532.89	3,759.75	
Total Income	74967.11	58640.29	65277.51	229561.94	212472.15	74,978.76	58,695.84	65,418.01	2,29,694.80	2,12,965.21	
Net Profit for the period Before Tax	10014.77	6212.56	9316.88	26894.22	24707.61	9,974.52	6,165.11	9,321.41	26,732.58	24,715.25	
Net Profit for the period After Tax	7127.57	4583.96	6910.58	19747.43	18456.60	7,101.03	4,542.87	6,909.72	19,598.16	18,466.49	
Paid up Equity Share Capital	907.40	907.40	907.40	907.40	907.40	907.40	907.40	907.40	907.40	907.40	
(Face value of₹ 2/- per share)											
Earnings Per Share (of₹ 2/- each)											
Basic and Diluted (₹) (not annualised)	15.97	10.11	14.93	43.80	39.98	15.88	10.01	14.94	43.45	39.99	



आयटीआय'मध्ये

The above Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 12,2025. These Financial Results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (as amended) (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other accounting practices and policies to the extent applicable.

The Board has recommended Final Dividend of ₹ 5/- (250%) per equity share of ₹ 2/- each, subject to approval of Shareholders at ensuing Annual General Meeting.

The above is an extract of the detailed format of Standalone and Consolidated Audited Financial Results for the guarter and year ended 31" March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of quarterly financial results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.siyaram.com FI137524%4/FI


Siyarams       Image: Siyarams         J. HAMPSTEAD       Image: Siyarams         J. HAMPSTEAD       CADINI         Mistair       OXEMBERG         Siyarams       DENKNIT         It a L Y       The power of presence         A DIFFERENT LEAGUE       THE POWEr OF PREsence	Place : Mumbai Date :12/05/2025				F	For SIYARAM SILK MILLS LTD Sd/ (Ramesh Poddar Chairman & Managing Directo DIN : 00090104
	Siyarams	J. HAMPSTEAD	ITALY	THE FINEST IN FASHION	ÓXEMBERG	<b>DEN</b> KNIT

-0

-4

15

26 23 20 81 21 91 51 71 13 15 01 54 12 61 66 where has been able to be the base of wheeler the test of wheele



# **Around the World**



Place : Mumbai

Date : May 12, 2025

## □ DEAL INCLUDES \$142B DEFENCE PACT, ENERGY-MINING PARTNERSHIP Trump's Take Home from Saudi Arabia: \$600-b **Investment** Commitment

We like each other a lot, US President tells Prince Salman

Concerning Rivadh: US President Donald Trump secured a \$600 billion commitment from Saudi Ara- bia on Tuesday to invest in the EUnited States after the oil po-Ewer rolled out the red carpet for him at the start of a tour of Gulf states.

Trump punched the air as he semerged from Air Force One to be greeted by Prince Mo-Ehammed bin Salman, who later signed an agreement with the president in Riyadh on energy, defence, mining and

- =other areas. Saudi Arabia's investment commitment includes what the US described as the largest \_\_defence sales agreement bet-Seen the allies, worth nearly
- =\$142 billion. Reuters reported in April the EUS was poised to offer the king-Edom an arms package worth well over \$100 billion. "I really -believe we like each other a lot," Trump said during a meeting Ewith the crown prince, Saudi
- Arabia's de facto ruler. E The US and Saudi Arabia
- Ehad discussed Riyadh's po-Etential purchase of Lockheed 🚥 =F-35 jets, two sources briefed
- Eon discussions told Reuters, Freferring to a military aircraft that the kingdom is long thought to have been interes-=ted in.
- N It was not immediately clear whether those aircraft were covered in the deal announ- create jobs in the U.S. Eced between the nations on =Tuesday.
- Trump, who is accompanied Business leaders at the by US business leaders including billionaire Elon Musk, will go on from Riyadh to Qa-



of the trip is on investment rat- the crown prince, who is otherher than security matters in the Middle East.

"While energy remains a cornerstone of our relationship, the investments and business opportunities in the kingdom have expanded and multiplied many, many timesover," Saudi investment minister Khalid al-Falih told a U.S.-Saudi in-

vestment forum. "As a result ... when Saudis and Americans join forces very good things happen, more often than not great things happen when those joint ventures happen," he said before Trump's arrival.

Trump called the Saudi crown prince a friend and said they have a good relationship, according to a pool report from the Wall Street Journal, Bashar Assad. Agencies

adding that Saudi investment would help

### **BIG INVESTMENTS**

investment forum included Larry Fink, the CEO of asset manage-

wise known as MbS, during a palace reception for the U.S. president. And joining Trump for a lunch with MbS were top

U.S. businessmen including Musk, the Tesla and SpaceX chief, and OpenAI CEO Sam Altman.

### WILL EASE SANCTIONS ON

SYRIA Trump also said on Tuesday that he will move to normalise relations and lift sanctions on Syria's new government to give the country "a chance at peace." Trump was set to meet Wednesday in Saudi Arabia with Syrian President Ahmad al-Sharaa, the onetime insurgent who last year led the overthrow of former leader

GSK

#### CIN No - L24230MH1984PLC034771 Registered Office: 102, Hyde Park, Saki Naka Road, Saki Vihar, Andheri (East), Mumbai - 400 072. Email: cs@blissgvs.com Website: www.blissgvs.com

BLISS GVS PHARMA LIMITED

## STATEMENT OF AUDITED STANDALONE AND **CONSOLIDATED FINANCIAL RESULTS** FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

The Board of Directors of the Company, at their meeting held on Monday, May 12, 2025 approved the audited standalone and consolidated financial results of the Company for the guarter and year ended March 31, 2025.

The full format of the financial results of the Company, are available on the Stock Exchanges websites at www.bseindia.com and www.nseindia.com and are also posted on the Company's website at https://blissgvs.com/investors/financials/quarterly-reports/ which can be accessed by scanning the Quick Response (QR) code.



For BLISS GVS PHARMA LIMITED SD/-GAGAN HARSH SHARMA MANAGING DIRECTOR Din: 07939421

Note: The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.

## GlaxoSmithKline Pharmaceuticals Limited

Registered Office: GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030 · Website: https://india-pharma.gsk.com/en-in/ Email: in.investorguery@gsk.com · Corporate Identity Number: L24239MH1924PLC001151

STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31<sup>57</sup> MARCH, 2025

-3

-5

20

49

8

4

46

45

4

43

9

58

28

2

-8

-8

24

33

2

2

2

6

\_0

4

3

6

- 40

-....

tar on Wednesday and the ment firm BlackRock, -United Arab Emirates on Stephen A. Schwartz-Thursday. man, CEO of asset ma-He has not scheduled a stop in nager Blackstone, and S\_Elsrael, a decision that has rai- Treasury Secretary sed questions about where the Scott Bessent. Eclose ally stands in Washing- Musk chatted briefly Eton's priorities, and the focus with both Trump and

# US April Inflation Cools as Some Tariffs Take Effect

-oled for the third straight the coming months.

Consumer prices rose ago, the Labor Department

ω said Tuesday, down from 2.4% in March and the Consumer

Ethan four years. On a monthly basis, pri- from a year

Eces rose modestly, increa- ago period, sing 0.2% from March to down from April after falling 0.1% the 2.4% in Mar

Eprevious month, the first drop in five years.

Grocery prices dipped creased a mild 0.2%. Econo-50.4% from March to April mists watch core prices be--Ein what will come as a reli- cause they typically provi-Eef to many people stret- de a better read on where Eching family budgets for prices are headed. Ethe basics. It was the big-

Eyears, Yet they are still 49% Mexico. AP

30000

<sup>&amp;-</sup> US Cuts Tariff on China
<sup>8</sup> Low-value Items to 54%

4-Hong Kong | Shanghai: The United States will cut The "de minimis" tariff for low-value items imported =from China, a White House =executive order said late on EMonday, further de-escalating a potentially damaging Etrade war between the Eworld's two largest econo--mies.

The tariff relief, which affects big Chinese e-commerand sent from China via pos-\_\_\_\_\_ce players including Shein and Temu, follows a deal tal service to previously en--Ebetween Beijing and Waster the US duty free and with Ehington to unwind most of minimal inspections. in the duties imposed on each In February, President Dozother's goods since early nald Trump ended the de April, after weekend talks minimis exemption by im-\$ posing a tax of 120% of the —in Geneva. Notes While their joint state- package's value or a plan ment in Geneva didn't men- ned flat fee of \$200. \_tion the de minimis duties, the White House order rele- BOEING CAN FLY ased later said the levies China has removed a ban =will be reduced to 54% from on airlines taking delivery =120% for items valued at up of Boeing planes after the =to \$800 sent from China via United States and China =postal services, with a flat agreed a temporary cut Free of \$100 to remain, star- steep tariffs, Bloomber \_ting from May 14. News reported on Tuesda Carriers can pay either the citing sources familia -54% or the \$100 fee per pack- with the matter. age, industry experts said. Officials in Beijing hav The logistics companies or started to tell domestic ca in -freight forwarders collect riers and government Ethose tariff fees from sellers agencies this week that de Ein China in advance. The de liveries of aircraft made minimis exemption allowed the US can resume, the re-S Eitems valued at up to \$800 portsaid. Agencies

EWashington: Inflation co- higher than a year ago The report suggests the Emonth in April even after tariffshaven'tyetimpacted some of President Donald the prices of many items. Trump's tariffs took effect, Clothing costs fell 0.2% though economists and from March to April, while many business owners ex- new car prices were unpect inflation will climb in changed. Furniture costs jumped1.5%, however. Excluding the volatile fo-2.3% in April from a year od and energy categories, core prices were also muted, ri--smallest increase in more prices rose sing 2.8% 2.3% in April

in April compared with a year ago, the same as in March. On a monthly basis, they in-

Only some early tariffs Egest decline in food costs at imposed by Trump were in -home since September effect in April, including E2020, the government said. 25% duties on steel and alu-Egg prices fell sharply, de- minum and 25% on some Eclining12.7%, the most in 41 imports from Canada and

				Standalone					Consolidated		
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited) Year ended 31.03.2024	(Unaudited) 3 months ended 31.03.2025	(Unaudited)	(Unaudited)	(Audited)	(Audited)
	Particulars	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025			3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024
1	Revenue from continuing operations	96608	94636	91087	372349	340725	97437	94942	92980	374921	345371
2	Profit before Exceptional Items and tax	35490	30635	26631	124375	95265	35857	30810	26822	125519	95980
3	Exceptional Items [credit / (charge)]	:22	-	240	469	(14361)	( <b>1</b>		240	469	(14361)
4	Profit before tax	35490	30635	26871	124844	80904	35857	30810	27062	125988	81619
5	Net Profit after tax	26014	22858	19308	91906	58469	26287	22988	19448	92758	58996
6	Total comprehensive income for the period	25630	22976	19239	91640	58052	25903	23106	19379	92492	58579
7	Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941
8	Other Equity	-	1	-	177982	161468	1.7		-	178190	160823
9	Earnings Per Share (EPS) (of ₹ 10 each)										
	Basic and diluted EPS before Exceptional Items (₹)	15.35	13.49	11.29	54.01	40.83	15.52	13.57	11.37	54.52	41.14
	Basic and diluted EPS after Exceptional Items (₹)	15.35	13.49	11.39	54.24	34.51	15.52	13.57	11.48	54.76	34.83
			Not A	Annualised				Not	Annualised		

#### Notes:

1. The above is an extract of the detailed format of the Financial Results for the quarter and year ended March 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com. The same can be assessed by scanning the QR code. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 13<sup>th</sup> May, 2025. 3. The Board of Directors recommended a final Dividend of Rs. 42 per equity share of face value of Rs.10 each (Year ended 31<sup>st</sup> March 2024 Rs. 32 per equity share).



By Order of the Board Bhushan Akshikar Managing Director DIN: 09112346

Place: Mumbai Date: 13th May, 2025



CIN: L17116MH1978PLC020451

Regd. Office: H-3/2, MIDC, 'A' Road, Tarapur, Boisar, Dist. Palghar, PIN 401 506 (M.S.),

Phone - 022-3040 0500; Email - sharedept@siyaram.com; Website - www.siyaram.com

#### EXTRACT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER

AND YEAR ENDED 31<sup>st</sup> MARCH, 2025.

N (₹In Lakhs)

		S	TANDALO	NE	CONSOLIDATED					
PARTICULARS	Quarter Ended			Year Ended		Quarter Ended			Year Ended	
PARTICULARS		31.12.2024 (Unaudited)		31.03.2025 (Audited)	31.03.2024 (Audited)	31.03.2025 (Audited)	31.12.2024 (Unaudited)	31.03.2024 (Audited)		31.03.2024 (Audited)
Revenue from Operations	73607.75	57017.36	64636.93	222031.86	208717.60	73,619.22	57,072.91	64,777.49	2,22,161.91	2,09,205.46
OtherIncome	1359.36	1622.93	640.58	7530.08	3754.55	1,359.54	1,622.93	640.52	7,532.89	3,759.75
lotal Income	74967.11	58640.29	65277.51	229561.94	212472.15	74,978.76	58,695.84	65,418.01	2,29,694.80	2,12,965.21
Net Profit for the period Before Tax	10014.77	6212.56	9316.88	26894.22	24707.61	9,974.52	6,165.11	9,321.41	26,732.58	24,715.25
Net Profit for the period After Tax	7127.57	4583.96	6910.58	19747.43	18456.60	7,101.03	4,542.87	6,909.72	19,598.16	18,466.49
Paid up Equity Share Capital	907.40	907.40	907.40	907.40	907.40	907.40	907.40	907.40	907.40	907.40
Face value of ₹ 2/- per share)										
Earnings Per Share (of₹ 2/- each)										
Basic and Diluted (₹) (not annualised)	15.97	10.11	14.93	43.80	39.98	15.88	10.01	14.94	43.45	39.99

The above Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 12,2025. These Financial Results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (as amended) (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other accounting practices and policies to the extent applicable.

The Board has recommended Final Dividend of ₹ 5/- (250%) per equity share of ₹ 2/- each, subject to approval of Shareholders at ensuing Annual General Meeting.

The above is an extract of the detailed format of Standalone and Consolidated Audited Financial Results for the guarter and year ended 31" March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of quarterly financial results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.siyaram.com

Place : Mumbai Date :12/05/2025		第147 第147		S (Ramesh Podda) Chairman & Managing Direc DIN : 000901
, Siyarams	J. HAMPSTEAD WORLD'S HINEST MARINE & APPAREL A DIFFERENT LEAGUE	MiSTATR THE FINEST IN FASHION A Silvaram's Initiative	ÓXEMBERG	Siyaram's DENKNIT PREMIUM INDIGO KNIT

# Lack of growth triggers to weigh on Dr Reddy's

Lower margins also a key concern; stock has been underperformer in short, long term

#### RAM PRASAD SAHU Mumbai, 13 May

harma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of 2024-25 (Q4FY25), even as revenue growth remained healthy. Lower gross margin performance and muted domestic growth are key concerns. Most brokerages have a "sell" or "reduce" rating as there are uncertainties related to the development of a new product portfolio and the launch timelines.

The stock has been an underperformer compared to peers not only in the short term (three months, and six months) but also in the longer term. While the peer index, Nifty Pharma, has delivered a 70 per cent return over the past two years, the drug major's returns are at 20 per cent.

Near-term disappointment has been the margin performance in Q4. Gross margins were down 262 basis points (bps) sequentially, and fell over 400 bps compared to the year-ago quarter. This is the third consecutive fall in gross margins for Dr Reddv's.

Shashank Krishnakumar and Bhavya Gandhi of Emkay Research point out that the sharp sequential decline in gross margins validates their concern since Q2FY25 that gross margin might be on a secular downward traiectory.

While the gross margin decline in Q4 was partly attributed to oneoffs, the weakness is also a function of incremental pricing pressures in the core US portfolio, particularly the generic version of Subroxone (for opioid use dis-



\_130

#### **UNDER PRESSURE** — Dr Reddy's Laboratories

- Nifty Pharma **112.59** 120

110 \_100 90 - Base = 100 **97.28**  $^{
m J}$ . 80 Apr 30,'24 May 13,'25 Sources: Bloomberg, NSE

Revlimid. The brokerage has a "reduce" rating, with a target price

of ₹1.050. Its ability to maintain growth engines, given the impending dip in Revlimid sales (patent expiry in January 2026), is another key worry and will remain an overhang. After a lacklustre approval rate for key drugs in the last five years, the company is eyeing over 20 major launches in the US market over the next four years. Gaurav Tinani of Antique Stock Broking believes that the company has a tough transition ahead as it is in the early stages of a growth rebuild, aiming to counter the anticipated decline in

Revlimid sales. This transition involves navigating the complexities of development, timeline uncertainties for market formation for limited comgeneric variant of cancer drug and higher associated costs. The are priced in.

brokerage estimates operating profit margin to be 22.3 per cent for FY27, compared to the management's target of 25 per cent. It has maintained a "sell" rating on the stock, with a target price of ₹1,025.

Growth in the domestic market will be another concern area. The company's India business revenue grew by 16 per cent year-on-year (Y-o-Y), largely driven by the vaccine portfolio inlicensed from Sanofi, new product launches, and price increases. This was partially

offset by lower volumes. Excluding the Sanofi portfolio, domestic sales grew by just 6 per cent in the quarter due to headwinds in cardiac and gastrointestinal therapies. Analysts led by Alankar Garude of Kotak Institutional Equities pointed out that the company's domestic sales have demonstrated a seemingly healthy 10.5 per cent growth annually over FY17-FY24. However, adjusted for inlicensing, acquisitions and divestments, Dr Reddy's like-for-like organic domestic sales over FY17-FY24 is merely 7.5 per cent, they added.

The brokerage has a "reduce" rating, with a target price of ₹1,180. At current market prices, they believe the US pricing stability, upside in emerging markets from blood sugar-control formulation GLP-1 or glucagon-like peptide-1, order), the largest contributor after petition biosimilar opportunities, and healthy growth in the EU



## **DEFENCE FUNDS** Valuation risk: Avoid entering or do so via SIP with 10-yr horizon

#### SANJAY KUMAR SINGH

The Nifty India Defence Total Return Index (TRI) has risen 27.4 per cent over the past three months, outperforming the Nifty 50 TRI, which gained 8.2 per cent. Defence-focused mutual funds have mirrored this rally. The category includes one active fund, HDFC Defence Fund, with assets under management (AUM) of ₹5,487.27 crore, and passive schemes from three fund houses -Motilal Oswal, Aditya Birla Sun Life, and Groww. These schemes manage ₹9,133.82 crore collectively.

These funds invest in defence equipment and other stocks related to the defence sector "A look at the Nifty India Defence Index's constituents reveals that it is a highly concentrated, top-heavy index. There is also a paucity of listed names in this space," says Kaustubh Belapurkar, directormanager research, Morningstar initiative in the defence sector, which is a key driver for its growth," says Vishal Dhawan, chief financial planner, Plan Ahead Wealth Advisors.


**THE SMART INVESTOR 15** 

The recent border tensions with Pakistan could lead to a spike in India's defence budget. 'This would mean higher revenues and profits for the companies in this sector," says Abhishek Kumar, Securities and Exchange Board of India (Sebi) registered investment advisor and founder, SahajMoney.com. He adds that investing in these funds may also help investors diversify their portfolios beyond traditional sectors.

#### Concentration, valuation risk

Defence funds carry high concentration risk. "Both the index and the active fund in this space are driven by just a few stocks," savs Belapurkar.

Heavy inflows have driven many defence stocks up by 60-70 per cent annually over five years, leading to expensive valuations. "The current price-toearnings (P/E) ratio of the Nifty 50 is 22, while the Nifty India Defence Index is at 52. The price-to-book value for the two



indices is 4 and 13 respectively. Thus, the Nifty Defence Index's valuations are more than two-three times the Nifty 50's," says Dhawan.

HDFC Defence Fund stopped accepting investments in mid-2024 — a development that investors should regard as a cautionary signal.

While defence firms are winning large orders, these typically take years to convert into revenue. "This could create a mismatch between the size of the order book and immediate profitability," says Dhawan.

Kumar highlights that these funds could take a hit if defence spending slows or due to elevated valuations.

#### **Right time to enter?**

Given the sharp run-up, most investors should avoid entering now. Only those with a strong fundamental view of the sector and its companies should invest. "These investors will have to be extremely patient and must be ready to ride out a down cycle before the sector moves up again," says Belapurkar.

Dhawan adds that only experienced investors with a high risk appetite, a grasp of market cycles, and comfort with volatility and timing risk should invest. Kumar cautions that conservative or inexperienced investors, those seeking stable returns, or those with short-term goals should stay away. Exposure to these funds should be taken in the satellite portfolio and limited to 5 per cent. Stagger your entry and have a minimum horizon of 10 years.

### Got a tax notice for a sudden income spike? What you must do

A notice from the income-tax department under Section 133(6) of the Income-tax Act, 1961 is commonly sent when there are high-value transactions, sudden income spikes, or large deductions that appear inconsistent with the income reported by the taxpayer. If you get one such notice, don't panic. ment Identification Number.

Steps to follow after receiving the notice Ankit Jain, partner at Ved Jain and Associates, says that the taxpayer should follow a structured response: VERIFY THE NOTICE: Ensure it has been issued by a valid income tax officer and carries a Docu-

UNDERSTAND THE REQUIREMENT: Read the notice carefully to determine the scope and type of information requested. **COMPILE DOCUMENTS:** Gather all relevant data and check for accuracy SUBMIT THE RESPONSE: The information should be furnished via the Income Tax e-filing portal. SEEK MORE TIME IF NEEDED: If doc-

uments can't be provided within the deadline, Jain advised sending a formal Naveen Wadhwa, vice-president transparency.

1.755.22

1.756.61

400.00

1.39

432.03

432 03

400.00

1.749.17

1,751.95

400.00

2.78

COMPILED BY AMIT KUMAR



Read full report here: mybs.in/2en0iex

#### Published in respect of this NIT through any other media. Last Date & Time for submission of bids : 03.06.2025 till 14:00 Hrs 03.06.2025 at 15:00 Hrs Date & Time of opening of bids Dy. General Manager (C&P) 6th Floor, Tower1, NBCC Office Complex, East Kidwai Nagar, New Delhi-110023. Ph.- 011-61901906 / 61901953

Ph:+91 94888 10404

**STATE BANK OF INDIA** 

Investment Research India.

#### Sound prospects

Jefferies estimates India's defence sector opportunity at \$100-120 billion over the next five-six years, with growth proiected at 13 per cent compounded annually from financial vear (FY) 2022-23 to FY2030. In FY24, domestic defence production reached a record ₹1.3 trillion.

'With the trend of protectionism in defence spreading globally, the Indian government has launched the Make in India

**DEFENCE INDEX: ENJOYING A HOT STREAK** 

8.9 13.4 1-month 3-month 6-month 1-year

request for extension. How to avoid receiving one in the first place at Taxmann, recommended maintaining financial

#### FORM NO. CAA 2

[Pursuant to Section 230(3) of the Companies Act, 2013 and Rule 6 and 7 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016]

#### BEFORE THE NATIONAL COMPANY LAW TRIBUNAL DIVISION BENCH-II, CHENNAI. CA(CAA)/16(CHE)/2025

In the matter of Composite Scheme of Arrangement and Amalgamation Between Cura Healthcare Private Limited (Demerged Company) And Adonis Medical Systems Private Limited (Resulting/Transferee/Amalgamated Company) And 3I Medical Technologies Private Limited (Transferor/Amalgamating Company) And Their respective shareholders and creditors Adonis Medical Systems Private Limited, (CIN: U51397TN1998PTC121627) a Company incorporated under the Companies, Act, 1956, having its Registered Office at Refex Towers, 2nd Floor, 313, Valluvar Kottam High Road,

Sterling Road Signal, Nungambakkam, Chennai, Tamil Nadu 600034 ... 2nd Applicant /Resulting/Transferee/Amalgamated Company

#### ADVERTISEMENT OF NOTICE OF THE MEETING OF THE UNSECURED CREDITORS OF ADONIS MEDICAL SYSTEMS PRIVATE LIMITED

NOTICE is hereby given that by an order dated 29th April 2025, the National Company Law Tribunal, Division Bench-II, Chennai ('NCLT' or 'the Tribunal') has directed a meeting to be held of the Unsecured Creditors of Adonis Medical Systems Private Limited ('the Applicant Company' or 'the Resulting Company' or 'the Transferee Company' or 'the Amalgamated Company' or 'the Company' for the purpose of considering, and if thought fit, approving with or without modification, the Composite Scheme of Arrangement and Amalgamation proposed to be made between Cura Healthcare Private Limited (CIN: U51397TN2001PTC047385) and Adonis Medical Systems Private Limited (CIN: U51397TN1998PTC121627) and 3I Medical Technologies Private Limited (CIN: U33110TN2020PTC139683) and their respective shareholders and creditors ('the Scheme').

In pursuance of the said order and as directed therein, further notice is hereby given that a meeting of the Unsecured Creditors of the Company will be convened and held on Sunday, 15 June 2025 at 10:30 A.M through video conferencing or other audio-visual means ('VC/OAVM'). At such day, date and time, the said Unsecured Creditors of the Company are requested to attend.

The quorum for the Meeting shall be 35 (Thirty-five) in number. In case, the said quorum is not present at fixed time for meeting, the meeting shall be adjourned by half an hour and thereafter, the person(s) present for voting shall be deemed to constitute the quorum.

Copies of the said Scheme, and the Explanatory Statement required to be furnished under Section 230 and other applicable provisions of the Companies Act, 2013 can be obtained free of charge at the registered office of the Company

Unsecured Creditors entitled to attend and vote at the meeting, shall vote through remote e-voting or through e-voting facility made available during the meeting through VC/OAVM. The procedure and instructions for attending the meeting through means of VC/OAVM and for e-voting shall be communicated separately to the e-mail ID registered with the Company shortly.

The Tribunal has appointed Mr. Jayanth Viswanathan as the Chairperson of the said Meeting and M.S.Elamathi as the Scrutinizer of the said Meeting. The above-mentioned Scheme, if approved by the Meeting, will be subject to the subsequent approval of the NCLT.

Dated this 14th May 2025 at Chennai

Jayanth Viswanathan Chairperson appointed for the Meeting

Premises & Estate Dept., Local Head Office, 2nd Floor, II/1, Pt. J. N. Marg, Bhubaneswar-751001, Ph. No.: 0674-2394637, E-mail: agmpre.lhobhu@sbi.co.in DER No.: BHU/P&E/2025-26/05, DATED: 13.05.2025 A FRE-CURLIFICATION AND SELECTION OF HITECTURAL CONSULTANCY FIRM (CONSULTANT) DESIGN COMPETITION FOR CONSTRUCTION OF BANK'S RIED (B+S+4) BUILDING ON VACANT PLOT AT IDCO PLOT VAR LE, BHUBANESWAR UNDER BHUBANESWAR CIRCLE LTI STORIED remises & Estate Department, on behalf of SBI, invites offer in two bio vstem for appointment of Architectural Consultancy Firm (Consultant system for appointment of Architectural Consultancy Firm (Consultancy through design competition for upcoming construction of Bank's multi-store building(B+S+4) to accommodate LCPC, CCPC, CPPC & i-DAC a MANCHESWARI.E, Bhubaneswar, Khurda district, Odisha. The eligible and interested parties may download the prescribed application form from the Bank's website: "Bank.sbi->SBI in the news->Procurement news" The applications can be downloaded from 14.05.2025 to 04.06.2025 up to 15.00 Hrs and completely filled in application in the prescribed format along with all supporting documents should reach us in the aforesaid address of or before due date & time. The Bank reserves the right to reject/accept an or all the offers received without assigning any reason thereof. The addendum/corrigendum, if any will be published in the Bank's Website only. Place: Bhubaneswar, Date: 14.05.2025 Asst. General Manager (P&E)

8	Reserves (excluding Revaluation Reserve) as shown in the					
	Audited Balance Sheet of the previous year	-	-	-	15,225.16	13,536.09
9	Earning per share (Rs)					
	(not annualised expect for the year ended March 2019)					
	a. Basic	11.84	10.13	10.80	43.88	43.73
	Employee benefits expense	11.84	10.13	10.80	43.88	43.73
Not	es'					

473.43

474 82

400.00

1.39

405.11

407 88

400.00

2.78

Place : Chennai

Date : 13/05/2025

5

6

The Audited financial results have been reviewed by the Audit committee and approved by the board of directors at their respective meeting, held on 13-05-2025. The financial results are prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013

2 The company is engaged in the sole activity of carrying on the business of 'Promotion and Maintenance of Software Technology Park" and therefore, has only one reportable segment in accordance with Ind AS 108 "Operating Segments". Hence, no separate segment reporting is applicable to the company.

3 Figures for the guarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2025 and 31 March 2024 respectively and the published year to date figures for nine months ended 31 December 2024 and 31 December 2023 respectively

4 Previous year/period's figures have been regrouped/recast, wherever necessary, to confirm to the classification of the current year/period's classification

For and on behalf of the Board Mrs. Unnamalai Thiagaraian Managing Director (DIN:00203154)

(₹ in Lakhs)

## GSK

nsbi

### **GlaxoSmithKline Pharmaceuticals Limited**

Net Profit for the period after tax (after exceptional items)

Equity Share Capital (face value of Rs.10 per share)

Total Comprehensive Income for the period [Comprising Profit for the

period (after tax) and Other Comprehensive Income (after tax)]

Other comprehensive income (net of tax)

Registered Office: GSK House. Dr. Annie Besant Road. Worli, Mumbai 400030 • Website: https://india-oharma.gsk.com/en-in/ Email: in.investorquery@gsk.com · Corporate Identity Number: L24239MH1924PLC001151

#### STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31<sup>ST</sup> MARCH, 2025

				Standalone					Consolidated		. ,
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
	Particulars	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024	3 months ended 31.03.2025	3 months ended 31.12.2024	Corresponding 3 months ended 31.03.2024	Year ended 31.03.2025	Year ended 31.03.2024
1	Revenue from continuing operations	96608	94636	91087	372349	340725	97437	94942	92980	374921	345371
2	Profit before Exceptional Items and tax	35490	30635	26631	124375	95265	35857	30810	26822	125519	95980
3	Exceptional Items [credit / (charge)]	-	-	240	469	(14361)	-	-	240	469	(14361)
4	Profit before tax	35490	30635	26871	124844	80904	35857	30810	27062	125988	81619
5	Net Profit after tax	26014	22858	19308	91906	58469	26287	22988	19448	92758	58996
6	Total comprehensive income for the period	25630	22976	19239	91640	58052	25903	23106	19379	92492	58579
7	Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941
8	Other Equity	-	-	-	177982	161468	-	-	-	178190	160823
9	Earnings Per Share (EPS) (of ₹ 10 each)										
	Basic and diluted EPS before Exceptional Items (₹)	15.35	13.49	11.29	54.01	40.83	15.52	13.57	11.37	54.52	41.14
	Basic and diluted EPS after Exceptional Items (₹)	15.35	13.49	11.39	54.24	34.51	15.52	13.57	11.48	54.76	34.83
			Not A	Annualised				Not /	Annualised		

#### Notes:

1. The above is an extract of the detailed format of the Financial Results for the quarter and year ended March 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com. The same can be assessed by scanning the QR code.

2. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 13th May, 2025.

3. The Board of Directors recommended a final Dividend of Rs. 42 per equity share of face value of Rs. 10 each (Year ended 31st March 2024 Rs. 32 per equity share).

By Order of the Board

Bhushan Akshikar Managing Director DIN: 09112346



Place: Mumbai Date: 13th May, 2025